# US 2006/0069035 A1 · Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0069035 A1
- Document ID: US20060069035A1
- Status: Published application
- Kind: A1
- Application number: 11/210,017
- Filed: 2005-08-23
- Published: 2006-03-30
- Earliest claimed: 2002-05-08
- Inventors: Abd. Al-Roof Higazi
- Web page: https://patentgrep.com/patent/US20060069035A1

## CPC

- A61K 38/166: {Streptokinase}
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to compositions of the polypeptide EEIIMID and one or more fibrinolytic agents selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. The invention further relates to methods of enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, or prolonging the half lives of the fibrinolytic agents by adding EEIIMD.

## Claims

### Claim 1

A composition including an effective amount of the polypeptide EEIIMD in the range of 2 μM to 10 μM, and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity.

### Claim 2 (depends on 1)

The composition acoording to claim 1, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

A method of enhancing the fibrinolytic activity of a fibrinolytic agent, said method comprising administering in vitro an effective amount of the polypeptide EEIIMD in the range of 2 uM to 10 uM, to enhance the activity and a suitable amount of a fibrinolytic agent to induce the desired level of fibrinolytic activity.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the fibrinolytic agent comprises scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisolylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative.

### Claim 9

(canceled)

### Claim 10

(canceled)
